Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

The role of biomarkers in the choice of therapy in breast cancer

verfasst von: Brigitte Mlineritsch, MD, Sigrun Ressler, MD, Prof. Richard Greil, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.CrossRefPubMed Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.CrossRefPubMed
3.
Zurück zum Zitat Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.CrossRefPubMed Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.CrossRefPubMed
4.
Zurück zum Zitat Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46.CrossRefPubMed Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46.CrossRefPubMed
5.
Zurück zum Zitat Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36.CrossRefPubMed Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36.CrossRefPubMed
6.
Zurück zum Zitat Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.CrossRefPubMed Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.CrossRefPubMed
7.
Zurück zum Zitat Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102.CrossRefPubMed Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102.CrossRefPubMed
8.
Zurück zum Zitat Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRefPubMed Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRefPubMed
9.
Zurück zum Zitat Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.CrossRefPubMed Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.CrossRefPubMed
10.
Zurück zum Zitat Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918.CrossRefPubMed Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918.CrossRefPubMed
11.
Zurück zum Zitat Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7.CrossRef Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7.CrossRef
12.
Zurück zum Zitat Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15. Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15.
13.
Zurück zum Zitat Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72.CrossRef Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72.CrossRef
14.
Zurück zum Zitat Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62.CrossRef Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62.CrossRef
15.
Zurück zum Zitat Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69.PubMed Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69.PubMed
16.
Zurück zum Zitat Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7.CrossRef Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7.CrossRef
17.
Zurück zum Zitat Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.CrossRefPubMed Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.CrossRefPubMed
18.
Zurück zum Zitat Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.CrossRefPubMed Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.CrossRefPubMed
19.
Zurück zum Zitat Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823.CrossRefPubMed Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823.CrossRefPubMed
20.
Zurück zum Zitat Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMed Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMed
21.
Zurück zum Zitat Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988.CrossRefPubMed Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988.CrossRefPubMed
22.
Zurück zum Zitat Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.CrossRefPubMed Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.CrossRefPubMed
23.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed
24.
Zurück zum Zitat Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62.CrossRefPubMed Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62.CrossRefPubMed
25.
Zurück zum Zitat Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74.CrossRefPubMed Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74.CrossRefPubMed
26.
Zurück zum Zitat Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011. Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011.
27.
Zurück zum Zitat Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefPubMed Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefPubMed
28.
Zurück zum Zitat Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.CrossRefPubMed Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.CrossRefPubMed
29.
Zurück zum Zitat Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157. Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157.
Metadaten
Titel
The role of biomarkers in the choice of therapy in breast cancer
verfasst von
Brigitte Mlineritsch, MD
Sigrun Ressler, MD
Prof. Richard Greil, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0027-y

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe